Clinical Trials Logo
  1. Home
  2. Smoldering Plasma Cell Myeloma
  3. NCT02960555

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Smoldering Plasma Cell Myeloma Clinical Trial

Official title:
Phase II Trial of Isatuximab (SAR650984) With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Clinical Trial Summary

This is a multi-center, open label, phase II study designed to evaluate the efficacy of isatuximab with or without lenalidomide when given to patients with high risk smoldering multiple myeloma.

Clinical Trial Description

PRIMARY OBJECTIVE: - To determine the rate of response according to the International Myeloma Working Group Criteria. SECONDARY OBJECTIVES: - To determine progression free survival (PFS) at 2 years. - To determine overall survival (OS). - To determine duration of response (DOR). - To determine the clinical benefit rate (CBR). - To evaluate safety of single agent treatment in this population - To evaluate safety of single agent treatment in this population. - To evaluate the immunogenicity of isatuximab. OUTLINE: Patients on single agent cohort receive isatuximab intravenously (IV) over 5 hours on day 1 of cycle 1, and over 3 hours thereafter on days 8, 15, and 22 of cycle 1, on days 1 and 15 of cycles 2-6, and on day 1 of subsequent cycles. Patients on Combination Cohort with Lenalidomide receive isatuximab as in single agent cohort plus Lenalidomide po 21/28 days during cycles 1-6 only. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6-12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02960555
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 8, 2017
Completion date April 30, 2030
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03937635 - Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma Phase 3
Active, not recruiting NCT04370483 - Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma Early Phase 1
Terminated NCT02353572 - Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05014646 - Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients Phase 2
Active, not recruiting NCT05288062 - Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma Phase 2
Recruiting NCT05136807 - Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
Recruiting NCT05312255 - Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma N/A
Active, not recruiting NCT02603887 - Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma Early Phase 1
Active, not recruiting NCT03631043 - Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma Early Phase 1
Recruiting NCT02726750 - Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Withdrawn NCT03952832 - Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma Phase 2
Recruiting NCT04776395 - Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma Phase 2
Completed NCT02492750 - Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Phase 1